Purified Duck Embryo Rabies Vaccine: An Accelerated Schedule for Preexposure Immunization Against Rabies

Kenrad Edwin Nelson, Murray D. Batt, Vicharn Vithayasai, Sanit Makornkawkayoon, Kampol Panas-Amporn, John T. Anderson

Research output: Contribution to journalArticle

Abstract

Seroconversion and adverse reaction rates were studied in 92 persons given four or five doses in a two-week period of duck embryo rabies vaccine (DEV) or duck embryo rabies vaccine purified by ultracentrifugation (P-DEV). Mouse-neutralizing antibodies developed in 78 of 92 (84.8%) persons in these accelerated schedules. There were no significant differences in the frequency of antibody conversion or in geometric mean titers of antibody between persons given either vaccine. However, local and systemic adverse reactions were substantially less common with P-DEV. These data suggest that four or five doses of DEV or P-DEV given in a two-week course can be used for preexposure prophylaxis in situations where the more drawn-out regimens would result in continuation of a high-risk of rabies exposure. The antibody response of persons given this more accelerated regimen must be determined. (JAMA 238:218-220, 1977).

Original languageEnglish (US)
Pages (from-to)218-220
Number of pages3
JournalJournal of the American Medical Association
Volume238
Issue number3
DOIs
StatePublished - Jul 18 1977
Externally publishedYes

Fingerprint

Rabies Vaccines
Immunization Schedule
Ducks
Rabies
Embryonic Structures
Antibodies
Ultracentrifugation
Neutralizing Antibodies
Antibody Formation
Appointments and Schedules
Vaccines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Purified Duck Embryo Rabies Vaccine : An Accelerated Schedule for Preexposure Immunization Against Rabies. / Nelson, Kenrad Edwin; Batt, Murray D.; Vithayasai, Vicharn; Makornkawkayoon, Sanit; Panas-Amporn, Kampol; Anderson, John T.

In: Journal of the American Medical Association, Vol. 238, No. 3, 18.07.1977, p. 218-220.

Research output: Contribution to journalArticle

Nelson, Kenrad Edwin ; Batt, Murray D. ; Vithayasai, Vicharn ; Makornkawkayoon, Sanit ; Panas-Amporn, Kampol ; Anderson, John T. / Purified Duck Embryo Rabies Vaccine : An Accelerated Schedule for Preexposure Immunization Against Rabies. In: Journal of the American Medical Association. 1977 ; Vol. 238, No. 3. pp. 218-220.
@article{52726739e0514c9cbd8dc400188952dc,
title = "Purified Duck Embryo Rabies Vaccine: An Accelerated Schedule for Preexposure Immunization Against Rabies",
abstract = "Seroconversion and adverse reaction rates were studied in 92 persons given four or five doses in a two-week period of duck embryo rabies vaccine (DEV) or duck embryo rabies vaccine purified by ultracentrifugation (P-DEV). Mouse-neutralizing antibodies developed in 78 of 92 (84.8{\%}) persons in these accelerated schedules. There were no significant differences in the frequency of antibody conversion or in geometric mean titers of antibody between persons given either vaccine. However, local and systemic adverse reactions were substantially less common with P-DEV. These data suggest that four or five doses of DEV or P-DEV given in a two-week course can be used for preexposure prophylaxis in situations where the more drawn-out regimens would result in continuation of a high-risk of rabies exposure. The antibody response of persons given this more accelerated regimen must be determined. (JAMA 238:218-220, 1977).",
author = "Nelson, {Kenrad Edwin} and Batt, {Murray D.} and Vicharn Vithayasai and Sanit Makornkawkayoon and Kampol Panas-Amporn and Anderson, {John T.}",
year = "1977",
month = "7",
day = "18",
doi = "10.1001/jama.1977.03280030026014",
language = "English (US)",
volume = "238",
pages = "218--220",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Purified Duck Embryo Rabies Vaccine

T2 - An Accelerated Schedule for Preexposure Immunization Against Rabies

AU - Nelson, Kenrad Edwin

AU - Batt, Murray D.

AU - Vithayasai, Vicharn

AU - Makornkawkayoon, Sanit

AU - Panas-Amporn, Kampol

AU - Anderson, John T.

PY - 1977/7/18

Y1 - 1977/7/18

N2 - Seroconversion and adverse reaction rates were studied in 92 persons given four or five doses in a two-week period of duck embryo rabies vaccine (DEV) or duck embryo rabies vaccine purified by ultracentrifugation (P-DEV). Mouse-neutralizing antibodies developed in 78 of 92 (84.8%) persons in these accelerated schedules. There were no significant differences in the frequency of antibody conversion or in geometric mean titers of antibody between persons given either vaccine. However, local and systemic adverse reactions were substantially less common with P-DEV. These data suggest that four or five doses of DEV or P-DEV given in a two-week course can be used for preexposure prophylaxis in situations where the more drawn-out regimens would result in continuation of a high-risk of rabies exposure. The antibody response of persons given this more accelerated regimen must be determined. (JAMA 238:218-220, 1977).

AB - Seroconversion and adverse reaction rates were studied in 92 persons given four or five doses in a two-week period of duck embryo rabies vaccine (DEV) or duck embryo rabies vaccine purified by ultracentrifugation (P-DEV). Mouse-neutralizing antibodies developed in 78 of 92 (84.8%) persons in these accelerated schedules. There were no significant differences in the frequency of antibody conversion or in geometric mean titers of antibody between persons given either vaccine. However, local and systemic adverse reactions were substantially less common with P-DEV. These data suggest that four or five doses of DEV or P-DEV given in a two-week course can be used for preexposure prophylaxis in situations where the more drawn-out regimens would result in continuation of a high-risk of rabies exposure. The antibody response of persons given this more accelerated regimen must be determined. (JAMA 238:218-220, 1977).

UR - http://www.scopus.com/inward/record.url?scp=84944967429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944967429&partnerID=8YFLogxK

U2 - 10.1001/jama.1977.03280030026014

DO - 10.1001/jama.1977.03280030026014

M3 - Article

C2 - 577520

AN - SCOPUS:84944967429

VL - 238

SP - 218

EP - 220

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 3

ER -